HF therapies such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), beta-adrenergic blocking agents (BB), mineralocorticoid receptor antagonists (MRAs) and cardiac resynchronization therapy (CRT), are capable of slowing and even reverting cardiac remodelling [10,11,12,13,14], and are associated with significant reductions in morbidity and mortality in HF with reduced ejection fraction [15,16,17,18]. The gene discussed is NR3C2; the disease is hydrops fetalis.